RT Journal Article
SR Electronic
T1 Value of <sup>68</sup>Ga-DOTATOC and Carbidopa-Assisted <sup>18</sup>F-DOPA PET/CT for Insulinoma Localization
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 384
OP 388
DO 10.2967/jnumed.121.262401
VO 63
IS 3
A1 Imperiale, Alessio
A1 Boursier, Caroline
A1 Sahakian, Nicolas
A1 Ouvrard, Eric
A1 Chevalier, Elodie
A1 Sebag, Frédéric
A1 Addeo, Pietro
A1 Taïeb, David
YR 2022
UL http://jnm.snmjournals.org/content/63/3/384.abstract
AB Our objective was to assess the value of 68Ga-DOTATOC and carbidopa-assisted 18F-fluorodihydroxyphenylalanine (18F-DOPA) in 21 hypoglycemic patients. Methods: All patients who underwent 68Ga-DOTATOC or carbidopa-assisted 18F-DOPA PET/CT for suspicion of insulinoma from January 2019 to January 2021 were retrospectively analyzed. A final diagnosis of insulinoma was determined by pathologic reports or consensus. Results: During the study period, 21 patients underwent both 68Ga-DOTATOC and 18F-DOPA PET/CT. A final diagnosis of insulin-secreting tumor was reached in 12 cases, including 11 insulinomas and 1 small mixed neuroendocrine/nonneuroendocrine neoplasm. 18F-DOPA and 68Ga-DOTATOC PET/CT were positive in 5 (45%) and 7 (64%) of 11 cases, respectively, with 4 concordant positive findings. Moreover, 1 insulinoma was visualized exclusively by 18F-DOPA PET/CT and 3 by 68Ga-DOTATOC PET/CT only. 18F-DOPA and 68Ga-DOTATOC PET/CT were falsely positive in 1 nonfunctioning pancreatic neuroendocrine tumor. Conclusion: When 68Ga-exendin-4 is not available, 68Ga-somatostatin receptor PET/CT should be the first choice for insulinoma functional imaging.